

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040210 A3

(51) International Patent Classification⁷: **C07K 14/54**,
C12N 15/24, 15/62, A61K 38/20, 31/713

Amanda [CH/FR]; Sous Chens, F-74140 Chens Sur
Leman (FR). SHAW, Jeffrey [TT/CH]; Chemin Thury 10,
CH-1206 Geneva (CH).

(21) International Application Number:
PCT/EP2004/052637

(74) Agent: Serono International SA, Intellectual Property,
Juergen Hassa; Serono International SA, 12, Chemin des
Aulx, CH-1228 Plan-les-Ouates (CH).

(22) International Filing Date: 22 October 2004 (22.10.2004)

(25) Filing Language: English

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(26) Publication Language: English

(30) Priority Data:
03103909.2 22 October 2003 (22.10.2003) EP



(71) Applicant (*for all designated States except US*): Applied
Research Systems ARS Holding N.V. [NL/NL]; Pieter-
maai 15, Curacao (AN).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): PROUDFOOT,

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,

[Continued on next page]

(54) Title: NOVEL CXCL8 ANTAGONISTS



(57) Abstract: Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity in vivo, thereby providing therapeutic compositions for use in the treatment or prevention of CXCL-8-related diseases.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

23 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.